SEARCH

SEARCH BY CITATION

References

  • 1
    Fleisch H 1991 Bisphosphonates: Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease Drugs 42: 919944.
  • 2
    Plosker GL, Goa KL 1994 Clodronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease Drugs 47: 945982.
  • 3
    Pentikäinen PJ, Elomaa I, Nurmi A-K, Kärkkäinen S 1989 Pharmacokinetics of clodronate in patients with metastatic breast cancer Int J Clin Pharmacol Ther Toxicol 27: 222228.
  • 4
    Conrad KA, Lee SM 1981 Clodronate kinetics and dynamics Clin Pharmacol Ther 30: 114120.
  • 5
    Yakatan GJ, Poynor WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RF et al. 1982 Clodronate kinetics and bioavailability Clin Pharmacol Ther 31: 402410.
  • 6
    Saha H, Castrén-Kortekangas P, Ojanen S, Juhakoski A, Tuominen J, Tokola O, Pasternack A 1994 Pharmacokinetics of clodronate in renal failure J Bone Miner Res 9: 19531958.
  • 7
    Castrén-Kortekangas P, Aranko K, Hanhijärvi H, Juhakoski A 1994 Steady state bioavailability of clodronate - pharmacokinetics of 800 mg clodronate (Bonefos® capsule) after a single and repeated oral dose. Leiras, Study Report 92551.
  • 8
    Steinijans VW, Hauschke D, Jonkman JHG 1992 Controversies in bioequivalence studies Clin Pharmacokinet 22: 247253.
  • 9
    (Confidence interval analysis (CIA). Version 1.2. 1992 BMJ Publishing Group, London, U.K.
  • 10
    Jones B, Kenward MG 1989 The 2 × 2 cross-over trial with continuous data. In: JonesB, KenwardMG Design and analysis of cross-over trials. Chapman and Hall, Suffolk, U.K., pp. 1688.
  • 11
    Hauschke D, Steinijans VW, Diletti E 1990 A distribution-free procedure for the statistical analysis of bioequivalence studies Int J Clin Pharmacol Ther Toxicol 28: 7278.
  • 12
    Edwards OM, Bayliss RIS, Millen S 1969 Urinary creatinine excretion as an index of the completeness of 24-hour urine collections Lancet ii: 11651166.